.Pharmacolibrary.Drugs.ATC.J.J05AH04

Information

Laninamivir is a neuraminidase inhibitor antiviral drug primarily used for the treatment and prophylaxis of influenza A and B. It is currently approved and used in Japan and some other regions but not in the United States or Europe. The drug is known for its long-acting effect, enabling single-dose inhalation therapy.

Pharmacokinetics

Pharmacokinetic data based on healthy adult volunteers after single inhaled administration.

References

1. Yoshihara, K, et al., & Kubo, Y (2013). Population pharmacokinetics of laninamivir and its prodrug laninamivir octanoate in healthy subjects and in adult and pediatric patients with influenza virus infection. Drug metabolism and pharmacokinetics 28(5) 416–426. DOI:10.2133/dmpk.dmpk-12-rg-115 PUBMED:https://pubmed.ncbi.nlm.nih.gov/23574886

2. Toyama, K, et al., & Ishizuka, H (2018). Intrapulmonary Pharmacokinetics of Laninamivir, a Neuraminidase Inhibitor, after a Single Nebulized Administration of Laninamivir Octanoate in Healthy Japanese Subjects. Antimicrobial agents and chemotherapy 62(1) –. DOI:10.1128/AAC.01722-17 PUBMED:https://pubmed.ncbi.nlm.nih.gov/29061751

3. Alshammari, MK, et al., & Alanazi, AA (2023). A Systematic Review of Clinical Pharmacokinetics of Inhaled Antiviral. Medicina (Kaunas, Lithuania) 59(4) –. DOI:10.3390/medicina59040642 PUBMED:https://pubmed.ncbi.nlm.nih.gov/37109600

Revisions

• 06/2025 initial generated model